Appili Therapeutics Inc.
APLIF
OTC PK
Weiss Ratings | APLIF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Rating | ||||
Reward Index | Very Weak | |||
Risk Index | Weak | |||
Risk Grade | D- | |||
Reward Grade | E | |||
Rating Factors | APLIF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Dividend Index | -- | |||
Growth Index | Good | |||
Efficiency Index | Very Weak | |||
Solvency Index | Weak | |||
Total Return Index | Very Weak | |||
Volatility Index | Weak | |||
Beta / Standard Deviation | APLIF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Beta | 1.08 | |||
Price History | APLIF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
7-Day Total Return | -3.60% | |||
30-Day Total Return | 9.18% | |||
60-Day Total Return | -19.25% | |||
90-Day Total Return | -23.57% | |||
Year to Date Total Return | -17.05% | |||
1-Year Total Return | -32.06% | |||
2-Year Total Return | -74.97% | |||
3-Year Total Return | -97.33% | |||
5-Year Total Return | -- | |||
52-Week High % Change | -68.48% | |||
52-Week Low % Change | 46.91% | |||
Price | APLIF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
52-Week High Price | $0.08 | |||
52-Week Low Price | $0.02 | |||
52-Week Low Price (Date) | Feb 20, 2024 | |||
52-Week High Price (Date) | Jul 18, 2023 | |||
Valuation | APLIF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Market Cap | 2.69M | |||
Enterprise Value | 8.16M | |||
Price/Earnings (TTM) | -- | |||
Earnings Per Share (TTM) | -0.03 | |||
Earnings Per Share Growth | -60.86% | |||
Price/Earnings To Growth | -- | |||
Price/Sales (TTM) | 3.40 | |||
Price/Book (Q) | -0.39 | |||
Enterprise Value/Revenue (TTM) | 10.11 | |||
Price | $0.02 | |||
Enterprise Value/EBITDA (TTM) | -1.39 | |||
Enterprise Value/EBIT | -1.38 | |||
Market Cap Category | Nano Cap | |||
Dividends and Shares | APLIF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Shares Outstanding | 121.27M | |||
Dividend Yield | -- | |||
Div. Per Share (Most Recent) | -- | |||
Dividend Per Share (TTM) | -- | |||
Payout Ratio (TTM) | -- | |||
Dividend Per Share (Most Recent) | -- | |||
Company Info | APLIF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Phone Number | 902-442-4655 | |||
Address | #21-1344 Summer Street Halifax, NS B3H 0A8 | |||
Website | www.appilitherapeutics.com | |||
Country | Canada | |||
Year Founded | 2015 | |||
Profitability | APLIF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Operating Margin (TTM) | -730.03% | |||
Profit Margin | -465.76% | |||
Management Effectiveness | APLIF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Return on Assets | -228.01% | |||
Return on Equity | -- | |||
Income Statement | APLIF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Revenue (TTM) | 850.20K | |||
Total Revenue (TTM) | 850.20K | |||
Revenue Per Share | $0.01 | |||
Gross Profit (TTM) | 850.20K | |||
EBITDA (TTM) | -6.20M | |||
EBIT (TTM) | -6.21M | |||
Net Income (TTM) | -3.96M | |||
Net Income Avl. to Common (TTM) | -3.96M | |||
Total Revenue Growth (Q YOY) | -- | |||
Earnings Growth (Q YOY) | 94.20% | |||
EPS Diluted (TTM) | -0.03 | |||
EPS Diluted Growth (Q YOY) | 94.34% | |||
Balance Sheet | APLIF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Cash and Short-Term Inv. (Q) | 456.50K | |||
Cash Per Share (Q) | $0.00 | |||
Total Current Assets (Q) | 1.46M | |||
Total Preferred Equity (Q) | -- | |||
Total Equity (Q) | -7.44M | |||
Current Ratio (Q) | 0.460 | |||
Book Value Per Share (Q) | -$0.06 | |||
Total Assets (Q) | 1.49M | |||
Total Current Liabilities (Q) | 3.19M | |||
Total Debt (Q) | 6.07M | |||
Total Liabilities (Q) | 8.94M | |||
Total Common Equity (Q) | -7.44M | |||
Cash Flow | APLIF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
Cash from Investing (TTM) | -27.00K | |||
Cash from Financing (TTM) | 1.72M | |||
Net Change in Cash (TTM) | -621.00K | |||
Levered Free Cash Flow (TTM) | -3.39M | |||
Cash from Operations (TTM) | -2.32M | |||